BiotechApril 2, 2026

Biotech Thursday: Gene Editors at 6-Year Lows, 69-Month Runways, $8M Insider Adds

Top 5 Pixie Picks

This Week's Setup

This week's biotech screen is clinical and capital-structure heavy: base editors and CRISPR names sit 30–54% off highs while runways stretch past five years and insiders keep adding into the drawdown.

Beam and CRISPR pair deep analyst upside with active trials, Regeneron anchors the list with profitable Dupixent-driven cash conversion, and Twist bridges discovery economics with insider buys and a bispecific platform tuck-in. The trade is in trial milestones and runway math, not sector mood.

The 8 Names

1. Beam Therapeutics Inc. (BEAM)

Stock Pixie Score 7.4/10 | 32.6% drawdown | 43-month cash runway | 108% analyst upside

Analysts see $51.20 ahead against a $24.57 price, backed by NEJM-published Phase 1/2 data for risto-cel in sickle cell disease and an active AATD trial recruiting for BEAM-302. Revenue jumped 120% year-over-year, gross margin runs at 85%, and the company holds 13× current assets to current liabilities.

Insiders added 1.3 million net shares over six months while short interest climbed to 24.2% of the float. Recent Form 4 filings show Evans John M. and Craig Beam both active in early April 2026. One executive sold $1.1 million, but the net six-month position is firmly bullish.

Negative FCF yield of 14.4% and 21.7% dilution year-over-year mean the cash runway is burning at pace. EV trades just 6% above net cash, so the market is pricing in very little franchise value beyond the balance sheet.

2. Twist Bioscience Corporation (TWST)

Stock Pixie Score 7.0/10 | 20% revenue growth | 50-month cash runway | 51% gross margin

Revenue growth of 20.3% and gross margin above 50% signal operating leverage is building. The company just added Invenra's bispecific platform to broaden discovery opportunities, and insiders scored 8.26 on the six-month composite (1.35% buy rate, 0.70% sell rate). Three Form 4 filings in the last 30 days show Dennis Cho and Paula Green stepping in.

Analyst consensus sees only 1.4% upside to $50.44, so the street is pricing in execution risk. Short interest sits at 23.5% of the float, and the stock is down 14% from its 52-week high despite the recent Q1 FY26 optimism.

EV trades 15× net cash, which means the market is already embedding significant growth expectations. If revenue growth decelerates or gross margin compresses, the valuation cushion evaporates quickly.

3. Regeneron Pharmaceuticals, Inc. (REGN)

Stock Pixie Score 7.0/10 | 16% ROIC | 4.75% FCF yield | 85% gross margin

ROIC of 16.3%, FCF yield of 4.75%, and gross margin of 85% make this the profit machine on the list. Normalized earnings yield (10-year) sits at 1.14%, and the company pays a small dividend (0.49% yield). Japan just approved Dupixent for bullous pemphigoid, extending the franchise into another indication.

Insiders added $6.45 million net over six months, with Arthur F. Ryan filing in early March 2026. Analyst net bullish sentiment is 70%, and the consensus target of $872.70 implies 14% upside from $762.54. Short interest is a muted 2.5% of float.

Revenue growth of just 1% year-over-year and a P/E of 18.4× signal the market is pricing in a mature growth profile. The stock is down only 7% from its 52-week high, so there's no distressed entry angle here.

4. CRISPR Therapeutics AG (CRSP)

Stock Pixie Score 6.9/10 | 38% drawdown | 69-month cash runway | 71% analyst upside

Analysts see $83.35 ahead against a $48.59 price, and the company holds 13× current assets to current liabilities with 69 months of cash runway. EV trades just 48% above net cash, which means the market is embedding minimal probability of commercial success despite the gene editing platform.

Insiders added 47,600 net shares over six months (5.05 composite score), with recent Form 4 activity from James Kasinger, Naimish Patel, and Samarth Kulkarni in March 2026. Short interest is 22.7% of float, so the bear case is crowded.

Revenue fell 100% year-over-year (likely lumpy partnership timing), and dilution ran 11.8% over the past year. Negative FCF yield of 8% and no earnings visibility mean this is a pure platform bet, not a cash-generative asset.

5. Tempus AI, Inc. (TEM)

Stock Pixie Score 6.6/10 | 83% revenue growth | 63% gross margin | 54% drawdown

Revenue surged 83% year-over-year, and gross margin sits at 63%. The company just reported ALERT cardiology trial results and expanded its Merck collaboration, pivoting its real-world data platform beyond oncology. Analysts see $75.43 ahead against a $47.32 price, implying 59% upside.

Insiders netted negative 836,000 shares over six months despite a 4.94 composite score, with recent Form 4 filings from Eric Lefkofsky, James Rogers, and David Epstein in March 2026. The sell activity outpaced buys (2.1% sell rate vs. 1.0% buy rate), which flags some internal caution.

Short interest is 22.2% of float, EV trades 12× net cash, and the stock is down 55% from its 52-week high. The AI diagnostics thesis is compelling, but the market is treating this as a show-me story with binary execution risk.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Biotech stocks.

6. Exelixis, Inc. (EXEL)

Stock Pixie Score 6.5/10 | 54% ROIC | 7.45% FCF yield | 96% gross margin

ROIC of 54%, FCF yield of 7.45%, and gross margin of 96% make this the cleanest income profile on the list. Normalized earnings yield (10-year) sits at 2.07%, and the company just bought back shares (dilution ran negative 6.8% year-over-year). Argus raised its target to $47, and Zacks flagged it as a strong growth stock.

Insiders added $8.03 million net over six months, with 2.2 million net shares purchased (80.5% buy rate vs. 20% sell rate). The stock is down only 12% from its 52-week high, so this is a quality compounder on a modest dip, not a distressed entry.

Analyst consensus sees only 7% upside to $46.83, and net bullish sentiment is split 50/50. Revenue growth of 7% year-over-year signals the cabozantinib franchise is maturing, and P/E of 15.7× leaves little room for multiple expansion.

7. Biogen Inc. (BIIB)

Stock Pixie Score 6.3/10 | 7.51% FCF yield | 76% gross margin | 16% analyst upside

FCF yield of 7.51%, gross margin of 76%, and a current ratio of 2.68 provide cash-generative stability. Biogen just closed a $5.6 billion buyout and is pivoting to early-stage assets. HC Wainwright raised its target to $237, and the stock is down only 12% from its 52-week high.

Insiders added $7.65 million net over six months, with 83,809 net shares purchased (55% buy rate vs. 2% sell rate). Short interest is a subdued 3% of float, so there's no crowded bear thesis here.

Normalized earnings yield (10-year) sits at just 0.61%, ROIC is 6.8%, and revenue growth is 2.2% year-over-year. Analyst net bullish sentiment is 46%, so the street is split on whether the early-stage pivot can reignite growth. P/E of 20.4× is not cheap for a mature profile.

8. Moderna, Inc. (MRNA)

Stock Pixie Score 6.0/10 | 37-month cash runway | 55% gross margin | analysts see -11% downside

Gross margin of 55% and a current ratio of 3.29 show the manufacturing base is still intact. The company just settled a patent dispute and is pivoting to cancer therapy, which refocused investor attention. Short interest is 18% of float, so there's fuel for a squeeze if execution improves.

Insiders added 897,271 net shares over six months (5.16 composite score), with recent Form 4 filings from James Mock, Stephane Bancel, and Shannon Klinger in early March 2026. Buy rate was 3.9% vs. 0.7% sell rate, which signals internal confidence despite the pivot uncertainty.

Analyst consensus sees $44.90 ahead against a $50.24 price (negative 11% implied return), and net bullish sentiment is just 12.5%. Revenue fell 40% year-over-year, negative FCF yield is 10.4%, and EV trades 2.6× net cash. Barclays just raised its target from $25 to $48, but the street is pricing in structural decline, not a turnaround.

What to Watch

Beam earnings expected in early May 2026; watch for BEACON trial enrollment updates and BEAM-302 AATD dosing milestones.
Regeneron Q1 2026 results due mid-April; Dupixent international expansion and pipeline readouts will drive the next leg.
Twist Bioscience fiscal Q2 2026 (likely late April); revenue guidance and Invenra platform integration timelines are the focus.
Moderna strategic update on cancer pipeline progression; any shift in burn rate or partnership announcements will reset the narrative.
Short squeeze risk on BEAM, TWST, CRSP, and TEM if fear subsides; all four carry 22–24% short interest and sit in deep drawdown zones.

Go Deeper

The biotech screener hunts for gene editors, platform plays, and commercial-stage names trading below intrinsic value with insider conviction. The top 8 show the contrarian entry points; Pro subscribers see valuation models, dilution trajectories, and trial catalyst calendars for the full pipeline.
Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full biotech screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.